Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Options ($5 call Oct-2022 for THTX Nasdaq)

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Sep 28, 2022 1:29pm

93 Views

Post# 34992735

RE:Options ($5 call Oct-2022 for THTX Nasdaq)

I can't validate the actual numbers as I haven't looked at prices, but it wouldn't surprise me some of the Hairdo guys followers speculate via options as well, and that with such little normal volume, an increase of 132% isn't that much anyway. It's some computer generated scribble to manufacture a headline or story. It's noise from those traders.

stephanedodier wrote: Hi,

Is anyone that has more background then me on option trading can validate this statement?

https://twitter.com/runaway_vol/status/1575129966240481282
(Theratechnologies Inc. $TH had an unusually high call volume of 7.5K this is 132.3K% of the 30d avg call volume of 5.7)

thanks